Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study

被引：0

作者：

Piedra, A. ^{[1
]}

Recio, S. Martinez ^{[1
]}

Gonzalez, A. Hernandez ^{[2
]}

Bueno, M. T. Moran ^{[2
]}

Arriola, E. ^{[3
]}

Recuero-Borau, J. ^{[4
]}

Dols, M. Cobo ^{[5
]}

Gonzalez, P. Cordeiro ^{[6
]}

Martinez, J. Mosquera ^{[7
]}

Garcia-Campelo, M. R. ^{[7
]}

Blanco, A. Calles ^{[8
]}

Alvarez, R. M. ^{[8
]}

Garcia, M. Zapata ^{[9
]}

Casado, M. D. Isla ^{[9
]}

Perez, A. Callejo ^{[10
]}

Gomez, P. Iranzo ^{[10
]}

Joaquin, A. Barba ^{[1
]}

Sullivan, I. G. ^{[1
]}

Felip, E. ^{[11
]}

Majem, M. ^{[1
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[2] Hosp Badalona Germans Trias & Pujol, Dept Med Oncol, ICO Inst Catala Oncol Badalona, Badalona, Spain

[3] Hosp Mar CIBERONC, Dept Med Oncol, Barcelona, Spain

[4] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain

[5] Hosp Reg Univ Malaga Carlos Haya, Dept Med Oncol, Malaga, Spain

[6] Inst Invest Biomed Coruna INIBIC, Dept Med Oncol, La Coruna, Spain

[7] CHUAC Complexo Hosp Univ A Coruna, Dept Med Oncol, La Coruna, Spain

[8] Hosp Gen Univ Gregorio Maranon, Dept Med Oncol, Madrid, Spain

[9] Hosp Clin Univ Lozano Blesa, Dept Med Oncol, Zaragoza, Spain

[10] Vall Hebron Univ Hosp VHIO, Dept Med Oncol, Barcelona, Spain

[11] Vall Hebron Univ Hosp VHIO, Med Oncol Serv, Lung Canc Unit, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2507

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1476P

引用

页数：2

共 50 条

[21] Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
Fiorelli, Alfonso
Vitiello, Fabiana
Morgillo, Floriana
Santagata, Mario
Spuntarelli, Chiara
Di Domenico, Marina
Santini, Mario
Bianco, Andrea
TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S618 - S620
[22] Clinical significance of inter-assay discrepancy in PD-L1 expression evaluation for the efficacy of pembrolizumab in advanced NSCLC patients with high PD-L1 expression
Miyakoshi, Jun
Kashima, Jumpei
Shirasawa, Masayuki
Torasawa, Masahiro
Matsumoto, Yuji
Masuda, Ken
Shinno, Yuki
Okuma, Yusuke
Yoshida, Tatsuya
Goto, Yasushi
Horinouchi, Hidehito
Shiraishi, Kouya
Kohno, Takashi
Yamamoto, Noboru
Yatabe, Yasushi
Ohe, Yuichiro
CANCER RESEARCH, 2024, 84 (06)
[23] Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab
Sanchez-Gastaldo, Amparo
Munoz-Fuentes, Miguel A.
Molina-Pinelo, Sonia
Alonso-Garcia, Miriam
Boyero, Laura
Bernabe-Caro, Reyes
TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (06) : 2509 - +
[24] Fast progression in high PD-L1 NSCLC treated with pembrolizumab in first-line: A prognostic scoring system based on clinical features
Passaro, A.
Giannarelli, D.
Bria, E.
Novello, S.
Galetta, D.
Gelibter, A. J.
Reale, M. L.
Carnio, S.
Vita, E.
Stefani, A.
Pizzutilo, P.
Stati, V.
Attili, I.
de Marinis, F.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S754 - S755
[25] PD-L1 expression and efficacy of pembrolizumab as monotherapy in NSCLC
Jorgensen, Jan Trost
CHINESE CLINICAL ONCOLOGY, 2020, 9 (04)
[26] Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression
Miyakoshi, Jun
Yoshida, Tatsuya
Kashima, Jumpei
Shirasawa, Masayuki
Torasawa, Masahiro
Matsumoto, Yuji
Masuda, Ken
Shinno, Yuki
Okuma, Yusuke
Goto, Yasushi
Horinouchi, Hidehito
Shiraishi, Kouya
Kohno, Takashi
Yamamoto, Noboru
Yatabe, Yasushi
Suzuki, Takuji
Ohe, Yuichiro
LUNG CANCER, 2024, 191
[27] Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab
Stares, Mark
Doyle, Emma
Chapple, Sally
Raynes, George
MacDonald, James
Barrie, Colin
Laird, Barry
MacKean, Melanie
Philips, Iain
LUNG CANCER, 2024, 189
[28] Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC
Wan, Ning
Zhang, Tian-tian
Hua, Si-hua
Lu, Zi-luo
Ji, Bo
Li, Li-xia
Lu, Li-qing
Huang, Wen-jie
Jiang, Jie
Li, Jian
CANCER MEDICINE, 2020, 9 (05): : 1683 - 1693
[29] The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors
Schakenraad, Alexandra
Hashemi, Sayed
Twisk, Jos
Houda, Ilias
Ulas, Ezgi
Daniels, Johannes M. A.
Veltman, Joris
Bahce, I.
LUNG CANCER, 2021, 162 : 36 - 41
[30] PD-L1 Very High Expression Associated with Clinical Outcome of Pembrolizumab Monotherapy of Advanced NSCLC with PD-L1 TPS of 50% or Greater
Itani, H.
Nigi, A.
Iwamoto, K.
Ito, Y.
Tanigawa, M.
Kondo, S.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S662 - S663

← 1 2 3 4 5 →